Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2021) 137 (24): 3327–3338.

https://doi.org/10.1182/blood.2020009617

Published: 2021

Includes: Supplemental data

Journal Articles

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target

Blood (2021) 137 (22): 3064–3078.

https://doi.org/10.1182/blood.2020005964

Published: 2021

Includes: Supplemental data

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Blood (2020) 135 (15): 1204–1213.

https://doi.org/10.1182/blood.2018884940

Published: 2020

Includes: Supplemental data

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Blood (2019) 134 (Supplement_1): 3039.

https://doi.org/10.1182/blood-2019-128706

Published: 2019

Journal Articles

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, Jennifer A. Woyach, MD, Richard R. Furman, MD, Peter Martin, FRCPC, MD MS, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Deborah M. Stephens, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, John M. Pagel, MD PhD, Dih-Yih Chen, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, Nitin Jain, MD, William G. Wierda, MD PhD

Blood (2018) 132 (Supplement 1): 692.

https://doi.org/10.1182/blood-2018-99-110451

Published: 2018

Journal Articles

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Andy Rawstron, PhD, Talha Munir, Kristian Brock, MSc, BSc, Nichola Webster, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Sophie Cramp, MSc, BSc, Rebecca Bishop, BSc, Surita Dalal, PhD, Ruth M De Tute, BSc,MSc, Oonagh Sheehy, Andrew Pettitt, FRCPath, PhD, Christopher P. Fox, MD PhD, Stephen Devereux, PhD, Christopher Fegan, MD, Donald MacDonald, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 181.

https://doi.org/10.1182/blood-2018-181

Published: 2018

Journal Articles

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Donald Macdonald, Christopher Fegan, MD, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Christopher P. Fox, MD PhD, Francesco Forconi, MD DM, PhD FRCPath, Talha Munir

Blood (2018) 132 (Supplement 1): 182.

https://doi.org/10.1182/blood-2018-182

Published: 2018

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19 + Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 887.

https://doi.org/10.1182/blood.V130.Suppl_1.887.887

Published: 2017

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

Blood (2017) 130 (Supplement 1): 498.

https://doi.org/10.1182/blood.V130.Suppl_1.498.498

Published: 2017

Journal Articles

Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study

Blood (2017) 130 (Supplement 1): 1746.

https://doi.org/10.1182/blood.V130.Suppl_1.1746.1746

Published: 2017

Journal Articles

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Blood (2017) 130 (Supplement 1): 1750.

https://doi.org/10.1182/blood.V130.Suppl_1.1750.1750

Published: 2017

Journal Articles

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Blood (2016) 128 (22): 234.

https://doi.org/10.1182/blood.V128.22.234.234

Published: 2016

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen

Blood (2016) 128 (22): 2049.

https://doi.org/10.1182/blood.V128.22.2049.2049

Published: 2016

Journal Articles

Uncoupling of BCR Internalization and Signaling in Treatment Naive and Btki-Treated Patients with Chronic Lymphocytic Leukemia

Eve M Coulter, PhD, Andrea Buggins, PhD MBA, Silvia Mele, PhD, Najeem Folarin, PhD, William Townsend, Kirsty Cuthill, FRCPath,MBBS,MRCP, Elizabeth Phillips, Piers Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD FRCP, FRCPath

Blood (2016) 128 (22): 191.

https://doi.org/10.1182/blood.V128.22.191.191

Published: 2016

Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD

Blood (2016) 128 (22): 2041.

https://doi.org/10.1182/blood.V128.22.2041.2041

Published: 2016

Journal Articles

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration

Marta Pasikowska, Elisabeth Walsby, Benedetta Apollonio, Kirsty Cuthill, Elizabeth Phillips, Eve Coulter, Maria Serena Longhi, Yun Ma, Deborah Yallop, Linda D. Barber, Piers Patten, Chris Fegan, Alan G. Ramsay, Chris Pepper, Stephen Devereux, Andrea G. S. Buggins

Blood (2016) 128 (4): 563–573.

https://doi.org/10.1182/blood-2016-01-683128

Published: 2016

Includes: Supplemental data

NARROW

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19 + Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Uncoupling of BCR Internalization and Signaling in Treatment Naive and Btki-Treated Patients with Chronic Lymphocytic Leukemia

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only